Why then are as many as one-half of CHA 2 DS 2 -VASc $2 patients not receiving effective treatment with oral anticoagulants, with many receiving aspirin instead (8) (9) (10) (11) (12) ? In this issue of the Journal, Hsu et al. Guidelines, on the basis of sound basic science, randomized controlled trials, clinical registries, metaanalyses, and the experience of experts, are by no means inviolate; clinicians are intended to use guidelines as analytic tools to assist in making rational decisions for each individual patient, weighing many factors, some more tangible than others, including patient choice and compliance. It is nonetheless concerning that the highly motivated, conscientious, and talented cardiologists working in quality-conscious institutions that contribute their data to the NCDR are not prescribing anticoagulation in one-third of their qualifying patients, as defined by our guidelines. This variance from guidelines does not appear to be related to true contraindication to anticoagulation, but may reflect a lack of appreciation that aspirin administration places a patient at significant risk for bleeding, while offering virtually no protection from stroke.
The PINNACLE registry does not detail the bleeding risk in these patients, but it seems unlikely that onethird had objective evidence of an unacceptable increase in the risk of serious bleeding as a contraindication to oral anticoagulation, especially because patients (n ¼ 17,627) deemed by their treating physicians "not able to be prescribed aspirin or oral anticoagulant therapy" were excluded from this analysis.
The risk of bleeding associated with anticoagulation is often cited as a contraindication for anticoagulation. 
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